Cancer cell survival

Section of breast tissue from a triple negative breast cancer (TNBC) patient, on the right, and healthy breast tissue, on the left. In the cancer patient, the cancer cells (indicated in light blue) surround cells in their microenvironment that express a high level of CD84 (indicated in purple)

burn the bridges of cancer

The institute's scientists revealed how aggressive breast cancer disrupts the immune response against it, and developed a treatment using an antibody that may be suitable for many types of cancer
When the scientists inhibited the production of the nucleic acid purine in the cancerous tissue (right), more T cells of the immune system penetrated it during the immunotherapy phase, compared to tissue that had not been pretreated with purine inhibitors (left). Photo production: Dr. Raya Elam

Vulnerability is acquired

Weizmann Institute of Science scientists, in collaboration with researchers from the National Cancer Institute and Ben-Gurion University of the Negev, recently found a genetic signature that differentiates between tumors that may respond to immunotherapy and tumors that are resistant to this treatment method. apart from a tool